MCID: URT028
MIFTS: 19

Ureter Transitional Cell Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Ureter Transitional Cell Carcinoma

MalaCards integrated aliases for Ureter Transitional Cell Carcinoma:

Name: Ureter Transitional Cell Carcinoma 12 15
Transitional Cell Carcinoma of Ureter 12 73
Ureteral Urothelial Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6888
NCIt 50 C4830
UMLS 73 C0577692

Summaries for Ureter Transitional Cell Carcinoma

MalaCards based summary : Ureter Transitional Cell Carcinoma, also known as transitional cell carcinoma of ureter, is related to infiltrating ureter transitional cell carcinoma and transitional cell carcinoma. An important gene associated with Ureter Transitional Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor). The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include kidney and colon.

Related Diseases for Ureter Transitional Cell Carcinoma

Diseases related to Ureter Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 infiltrating ureter transitional cell carcinoma 12.4
2 transitional cell carcinoma 10.2
3 enterocolitis 10.0

Symptoms & Phenotypes for Ureter Transitional Cell Carcinoma

Drugs & Therapeutics for Ureter Transitional Cell Carcinoma

Drugs for Ureter Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
3
Carboplatin Approved Phase 3,Phase 1 41575-94-4 10339178 38904 498142
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5 Immunologic Factors Phase 3,Phase 2,Phase 1
6 Immunoglobulin G Phase 3,Phase 1
7 Antibodies Phase 3,Phase 2,Phase 1
8 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
9 Immunoglobulins Phase 3,Phase 2,Phase 1
10 Antiviral Agents Phase 3,Phase 2
11 Immunosuppressive Agents Phase 3,Phase 2
12 Antimetabolites, Antineoplastic Phase 3,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2
14 Antimetabolites Phase 3,Phase 2
15 Angiogenesis Inhibitors Phase 3
16 Endothelial Growth Factors Phase 3
17 Mitogens Phase 3
18 Angiogenesis Modulating Agents Phase 3
19
Nivolumab Approved Phase 2,Phase 1 946414-94-4
20
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
21 tyrosine Phase 2
22 Antibodies, Blocking Phase 2
23
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
24 Protein Kinase Inhibitors Phase 2
25
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
26
Tremelimumab Investigational Phase 1 745013-59-6
27
Veliparib Investigational Phase 1 912444-00-9 11960529
28 Albumin-Bound Paclitaxel Phase 1
29 Antineoplastic Agents, Phytogenic Phase 1
30 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
31 Antimitotic Agents Phase 1
32 Liver Extracts Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Active, not recruiting NCT01993979 Phase 3 Chemotherapy
2 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
3 Sitravatinib and Nivolumab in Urothelial Carcinoma Study Recruiting NCT03606174 Phase 2 Sitravatinib;Nivolumab
4 Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Recruiting NCT03237780 Phase 2 Atezolizumab;Eribulin Mesylate
5 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Active, not recruiting NCT02178241 Phase 2 Eribulin Mesylate;Gemcitabine Hydrochloride
6 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Active, not recruiting NCT00749892 Phase 2 Erlotinib Hydrochloride
7 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Not yet recruiting NCT03513952 Phase 2 Atezolizumab
8 Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery Recruiting NCT02812420 Phase 1
9 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
10 Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Suspended NCT01366144 Phase 1 Carboplatin;Paclitaxel;Veliparib

Search NIH Clinical Center for Ureter Transitional Cell Carcinoma

Genetic Tests for Ureter Transitional Cell Carcinoma

Anatomical Context for Ureter Transitional Cell Carcinoma

MalaCards organs/tissues related to Ureter Transitional Cell Carcinoma:

41
Kidney, Colon

Publications for Ureter Transitional Cell Carcinoma

Articles related to Ureter Transitional Cell Carcinoma:

# Title Authors Year
1
Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports. ( 26442166 )
2015
2
Transitional cell carcinoma of ureter simulating left colonic malignancy-a rare case. ( 25972635 )
2015
3
Transitional cell carcinoma of ureter in a solitary functioning kidney. ( 24718012 )
2014
4
Enterocolitis related to chemotherapy with gemcitabine and cisplatin in patient with transitional cell carcinoma of ureter. ( 19686356 )
2009
5
Chromosome change in transitional cell carcinoma of ureter. ( 3943051 )
1986
6
Transitional cell carcinoma of ureter--case report. ( 6535047 )
1984
7
Case profile of the month. Transitional-cell carcinoma of ureter. ( 4417291 )
1974

Variations for Ureter Transitional Cell Carcinoma

Cosmic variations for Ureter Transitional Cell Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10988 TP53 urinary tract,ureter,carcinoma,transitional cell carcinoma c.772G>A p.E258K 17:7674191-7674191 10
2 COSM10662 TP53 urinary tract,ureter,carcinoma,transitional cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 10
3 COSM10648 TP53 urinary tract,ureter,carcinoma,transitional cell carcinoma c.524G>A p.R175H 17:7675088-7675088 10
4 COSM44567 TP53 urinary tract,ureter,carcinoma,transitional cell carcinoma c.647T>C p.V216A 17:7674884-7674884 10
5 COSM10722 TP53 urinary tract,ureter,carcinoma,transitional cell carcinoma c.853G>A p.E285K 17:7673767-7673767 10
6 COSM715 FGFR3 urinary tract,ureter,carcinoma,transitional cell carcinoma c.746C>G p.S249C 4:1801841-1801841 10
7 COSM718 FGFR3 urinary tract,ureter,carcinoma,transitional cell carcinoma c.1118A>G p.Y373C 4:1804372-1804372 10
8 COSM714 FGFR3 urinary tract,ureter,carcinoma,transitional cell carcinoma c.742C>T p.R248C 4:1801837-1801837 10

Expression for Ureter Transitional Cell Carcinoma

Search GEO for disease gene expression data for Ureter Transitional Cell Carcinoma.

Pathways for Ureter Transitional Cell Carcinoma

GO Terms for Ureter Transitional Cell Carcinoma

Sources for Ureter Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....